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Duborija-Kovačević N, Bochenek T,
Huys I and Miljković B (2020)
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1 Institute of Orthopaedic Surgery “Banjica”, University of Belgrade, Belgrade, Serbia, 2 Division of Clinical Pharmacology,
Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 3 Strathclyde Institute of Pharmacy and Biomedical
Sciences, Strathclyde University, Glasgow, United Kingdom, 4 Department of Public Health and Management, School of
Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa, 5 Department of Pharmacokinetics and
Clinical Pharmacy, University of Belgrade, Belgrade, Serbia, 6 Department of Clinical Pharmacy, IRCCS, ISMETT, Palermo,
Italy, 7 Hospital Pharmacy Department, Chania General Hospital, Crete, Greece, 8 Pharmacy Department, Heidelberg
University Hospital, Heidelberg, Germany, 9 Pharmacy Department, Tartu University Hospital, Tartu, Estonia, 10 Hospital
Pharmacy Department, Spitalul Clinic C. F. Cluj-Napoca, Cluj-Napoca, Romania, 11 Department of Pharmaceutical
Surveillance and Economics, University of Debrecen, Debrecen, Hungary, 12 Pharmacy Department, University Hospitals
Leuven, UZ Herestraat, Leuven, Belgium, 13 Department of Pharmaceutics and Central Clinical Pharmacy, Faculty of
Pharmacy, University of Pécs, Pécs, Hungary, 14 Hospital Pharmacy Department, The Cyprus Institute of Neurology and
Genetics, Nicosia, Cyprus, 15 Leeds Medicines Advisory Service, The Leeds Teaching Hospitals NHS Trust, St James's
University Hospital, Leeds, United Kingdom, 16 Sector for Medicinal Products, Agency for Medicines and Medical Devices of
Bosnia and Herzegovina, Banja Luka, Bosnia and Herzegovina, 17 Faculty of Medicine—Department of Pharmacy, University
of Banja Luka, Banja Luka, Bosnia and Herzegovina, 18 Hospital Pharmacy Department, Midland Regional Hospital,
Tullamore, Ireland, 19 Servicio de Farmacia, Hospital Universitario Infanta Sofía, Madrid, Spain, 20 Hospital Pharmacy
Department, Hôpital Antoine Béclère, Clamart, France, 21 Hospital Pharmacy Department, Clinical Centre of Serbia, Belgrade,
Serbia, 22 International Cooperation and Public Relation Department, Medicines and Medical Device Agency of Serbia,
Belgrade, Serbia, 23 Health Division, Berner Fachhochschule Health Professions Ernährung und Diätetik, Bern, Switzerland,
24 Department of Hospital Pharmacy, General Hospital Celje, Celje, Slovenia, 25 Hospital Pharmacy Department, Apotheke
der Barmherzigen Brüdere. U., Linz, Austria, 26 Pharmacy Department, University Clinic—State Hospital of Innsbruck,
Innsbruck, Austria, 27 Faculty of Social Sciences, The Graduate School of Business Administration, Tel Aviv, Israel,
28 Médecine Interne et Maladies Infectieuses, CHU de Poitiers, Poitiers, France, 29 Department of Public Health, Université
Droit et Santé Lille 2, Lille, France, 30 Hospital Pharmacy Department, General hospital “dr. Tomislav Bardek”, Koprivnica,
Croatia, 31 Nomeco-Hospital&Customer Service, Nomeco Commercial Affairs, Copenhagen, Denmark, 32 Strategic
Procurement and Supply of Pharmaceuticals, Amgros I/S, Copenhagen, Denmark, 33 Hospital Pharmacy Department,
Children's Clinical University Hospital, Riga, Latvia, 34 Department of Physical Medicine and Rehabilitation “Dr Miroslav
Zotović”, Banja Luka, Bosnia and Herzegovina, 35 National Center for Medicine Shortages in Hospitals, Oslo
universitetssykehus HF, Nydalen, Norway, 36 Certification Department, The Republic of Srpska Agency for Certification,
Accreditation and Quality Improvement in Health Care, Banja Luka, Bosnia and Herzegovina, 37 Department of
Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Banja Luka, Banja Luka, Bosnia and
Herzegovina, 38 Community Pharmacy Department, Pharmacy “Biljana”, Banja Luka, Bosnia and Herzegovina, 39 Division
DEFO, Finnish Medicines Agency, Helsinki, Finland, 40 Department of Surgery, Department of Medical Ethics, Medical Faculty
of the University of Montenegro, Podgorica, Montenegro, 41 Department of Pharmacology and Clinical Pharmacology,
Medical Faculty of the University of Montenegro, Podgorica, Montenegro, 42 Department of Drug Management, Faculty of
Health Sciences, Jagiellonian University Medical College, Krakow, Poland, 43 Department of Pharmaceutical and
Pharmacological Sciences, KU Leuven, Leuven, Belgiumin.org March 2020 | Volume 11 | Article 3571
Miljković et al. Medicine Shortages in Europe and Israel
Frontiers in Pharmacology | www.frontiersIntroduction: While medicine shortages are complex, their mitigation is more of a
challenge. Prospective risk assessment as a means to mitigate possible shortages, has
yet to be applied equally across healthcare settings. The aims of this study have been to:
1) gain insight into risk-prevention against possible medicine shortages among healthcare
experts; 2) review existing strategies for minimizing patient-health risks through applied
risk assessment; and 3) learn from experiences related to application in practice.
Methodology: A semi-structured questionnaire focusing on medicine shortages was
distributed electronically to members of the European Cooperation in Science and
Technology (COST) Action 15105 (28 member countries) and to hospital pharmacists
of the European Association of Hospital Pharmacists (EAHP) (including associated
healthcare professionals). Their answers were subjected to both qualitative and
quantitative analysis (Microsoft Office Excel 2010 and IBM SPSS Statistics®) with
descriptive statistics based on the distribution of responses. Their proportional
difference was tested by the chi-square test and Fisher's exact test for independence.
Differences in the observed ordinal variables were tested by the Mann-Whitney or Kruskal-
Wallis test. The qualitative data were tabulated and recombined with the quantitative data
to observe, uncover and interpret meanings and patterns.
Results: The participants (61.7%) are aware of the use of risk assessment procedures as
a coping strategy for medicine shortages, and named the particular risk assessment
procedure they are familiar with failure mode and effect analysis (FMEA) (26.4%), root
cause analysis (RCA) (23.5%), the healthcare FMEA (HFMEA) (14.7%), and the hazard
analysis and critical control point (HACCP) (14.7%). Only 29.4% report risk assessment as
integrated into mitigation strategy protocols. Risk assessment is typically conducted
within multidisciplinary teams (35.3%). Whereas 14.7% participants were aware of
legislation stipulating risk assessment implementation in shortages, 88.2% claimed not
to have reported their findings to their respective official institutions. 85.3% consider risk
assessment a useful mitigation strategy.
Conclusion: The study indicates a lack of systematically organized tools used to
prospectively analyze clinical as well as operationalized risk stemming from medicine
shortages in healthcare. There is also a lack of legal instruments and sufficient data
confirming the necessity and usefulness of risk assessment in mitigating medicine
shortages in Europe.Keywords: medicine shortage, risk assessment, mitigation strategy, substitution, EuropeINTRODUCTION
Shortages of medicines have been on the rise globally this century
(Gray and Manasse, 2012; American Society of Health-System
Pharmacists, 2014; The Society of Hospital Pharmacists of
Australia, 2017; Root, 2018; Miljkovic et al., 2019; Videau
et al., 2019). Due to their multifaceted nature, there are
currently over 26 definitions of medicine shortages from
manufacturers, wholesalers, regulators, and healthcare
providers (De Weerdt et al., 2015; Fox and McLaughlin, 2018).
Contributing factors to shortages stem from the unique nature of
the drug market itself, such as insufficient manufacturing
capacity, a shortage of active pharmaceutical ingredients, andin.org 2restricted distribution/allocation. These are all outside of the
control of the pharmacist. Nevertheless, pharmacy departments
may effectively manage drug shortages by implementing defined
strategies ahead of the occurrence of a shortage. (Kaakeh et al.,
2011; Ventola, 2011; Goldsack et al., 2014; DeWeerdt et al., 2017;
Fox and McLaughlin, 2018).
Risks from medicine shortages range from the basic risk of
not being able to provide a patient with the medicine to
providing a non-appropriate substitute thereby introducing the
complication of medication errors (Parenteral Drug Association
(PDA), 2014; Fox and McLaughlin, 2018). It is necessary to
distinguish several risks emerging from shortages: 1) its
occurrence; 2) treatment unavailable to the patient; andMarch 2020 | Volume 11 | Article 357
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clinical needs. However, all risks may be prospectively analyzed
separately for each medicine, based on the history of shortages,
type of a medicine, the patients affected, and available
alternatives (Canadian Pharmacists Association, 2010).
Medicine shortages have a direct impact on patient outcomes
through disrupting the continuity of patient care and potentially
deteriorating treatment outcomes originating from timely
scarcity of drug supply and substitution with a less safe and
effective alternative and the potential for medication errors
(Iyengar et al., 2016; De Weerdt et al., 2017; Rinaldi et al.,
2017; France Assos Santé, 2018; Phuong et al., 2019).
Consequently, risk management plays an important role in
healthcare settings via minimizing the likelihood of identified
risk-related consequences associated with drug shortages (The
Australian Council on Healthcare Standards (ACHS), 2013;
Iyengar et al., 2016; American Society of Health-System
Pharmacists, 2018; Root, 2018).
As stated by Acosta et al. (2019), managing medicine
shortages should not consist solely of creating systems
designed to gather information on the shortages themselves
but also proposing proactive solutions for ongoing and
emerging shortages (Acosta et al., 2019). Consequently, risk
assessment plays a crucial role in understanding and mapping
all risks emerging from potential drug shortages in respective
healthcare environments (Australian Government Department
of Health, 2018).
A comprehensive risk-based approach aimed at preventing and
managing shortages assists in tackling multiple aspects of medicine
shortages (Parenteral Drug Association (PDA), 2014). These risks
exist at the manufacturing and supply chain levels as well as in the
healthcare system itself. Risk management enables proactive risk
identification, assessment, and risk control emerging from
shortages, thereby reducing harm to patients (Parenteral Drug
Association (PDA), 2014). Triage of risks allows for shortages to
be proactively managed (Parenteral Drug Association (PDA), 2014).
It is carried out via categorizing a medicine's criticality based on its
therapeutic use/indication, patient clinical needs, likelihood of
occurrence, and availability of alternatives (Parenteral Drug
Association (PDA), 2014). Triage itself assists in the assessment of
risks emerging from shortages through proposing and prioritizing
risk corrective/control measures (Parenteral Drug Association
(PDA), 2014).
Risk assessment may be performed both retrospectively and
prospectively. Through incidence reporting and root cause
analysis (RCA) driving incidents are retrospectively and
meticulously analyzed so that their causes may be prevented in
the future. The method focuses on the event rather than the
process within which an incident occurs (Chiozza and Ponzetti,
2009). Conversely, prospective risk assessment, such as failure
mode and effect analysis (FMEA), healthcare failure and mode
effect analysis (HFMEA), hazard analysis and critical control
points (HACCP) serves to evaluate processes and the causes of
potential failures/risks/hazards, which may occur, to prioritize
and prevent them from occurrence (Bonnabry et al., 2005;
Chiozza and Ponzetti, 2009).Frontiers in Pharmacology | www.frontiersin.org 3Regardless of its prospective or retrospective nature, risk
assessment provides for the ability to manage risks in a
manner most suitable for each healthcare setting as well as
providing applicable solutions for containing and reducing
detected risks (Clarkson, 2010). The assessments should take
into account the causes of shortages, their duration, healthcare-
setting utilization patterns of the medicines affected, and
available substitutes. Successfully mitigating shortages also
requires clear channels of communication with other
healthcare professionals, particularly for the risk assessment's
output and mitigation plans (Root, 2018). Furthermore,
implementing processes systematically applied throughout a set
of tailored procedures is necessary and provides the context in
which all potential risks are identified, analyzed, evaluated,
assessed, monitored, and reviewed (The Australian Council on
Healthcare Standards (ACHS), 2013).
The majority of Council of Europe countries require that the
pharmaceutical industry or the marketing authorization holder
(MAH) inform their respective organization/institution
responsible if a medicine will be unavailable due to postponed
commerc ia l i za t ion , market withdrawal , change in
reimbursement schemes, or any other cause that might lead to
a shortage (Bochenek et al., 2017). Article 23a, 2nd paragraph of
EU Directive 2001/83/EC and article 27a, 2nd paragraph of
Directive 2001/82/EC both stipulate that the member country's
respective authority must be informed a minimum of two
months prior to the expected shortage (European Medicines
Agency (EMA) 2019b).
In 2014, both the pharmaceutical industry and European
health authorities under the auspices of European Medicine
Agency (EMA) and Parenteral Drug Association (PDA) jointly
proposed a set of activities to address medicine shortages that
were not solely based on notification strategies (Parenteral Drug
Association (PDA), 2014). They aimed to tackle shortages in a
prospective manner via preventative actions and communication
strategies oriented also to the production of medicines and their
quality assessment (Parenteral Drug Association (PDA), 2014).
The authors believe this to be the first time risk assessment has
been proposed as a mitigation strategy. Similarly, an initiative
proposed by the Institute for Safe Medication Practices (ISMP)
Canada was also based on prospective risk assessment aimed at
detecting risks of all possible shortages as well as reducing their
potential impact on patient health via failure mode and effect
analysis (FMEA) (Institute for Safe Medication Practices Canada,
2006). The concept of risk assessment is also present in the USA
and Australian [Therapeutics Goods Administration (TGA)]
guidelines, where the critical need of different medicines is
assessed in terms of shortage impact analysis [(the American
Society of Health System Pharmacists (ASHP)] and patient safety
risks (TGA) (Australian Government Department of Health,
2018; Fox and McLaughlin, 2018).
Rodriguez-Gonzalez et al. note that prospective risk assessment
is beneficial in regard to medication administration (Rodriguez-
Gonzalez et al., 2015). Therefore, such assessment may also be
extended into the risk due tomedicine shortages. In view of the first-
hand nature in which they have to deal with shortages, a detailedMarch 2020 | Volume 11 | Article 357
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other healthcare stakeholders, concerning risks is central to
minimizing the impact of shortages. Specifically, which shortages
pose the greatest risk to patient health and the potential solutions for
their management. Consequently, the aims of this study were firstly
to elucidate the concept of risk-prevention among healthcare
experts; secondly, ascertain existing strategies for minimizing risks
for patient health through risk assessment and their experiences
with implementing them. Thirdly, use the findings to provide
future directions.1Other medicines mentioned in which a risk assessment is conducted include:
digoxin, disulfiram, fluspirilene, neostigmine, remifentanil, sodiumchoride
solution, tranexamic acid and warfarin.METHODOLOGY
A survey was conducted between July, 2018, and March, 2019. It
was distributed via e-mail to members of the European
Cooperation in Science and Technology, COST Action 15105,
a research network of consisting of representatives from 28
member countries who are focused on research in medicine
shortages (COST, 2015; COST, 2018). The survey was also
provided to volunteering hospital pharmacists who are
members of the European Association of Hospital Pharmacists
(EAHP) and any of their associated colleagues (other healthcare
professionals) who chose to fill it out.
The survey included a semi-structured questionnaire of 38
questions across three sections, covering: (i) concepts of risk
assessment in healthcare settings; (ii) aspects of implementation
of risk assessment in medicine substitution due to medicine
shortages; and (iii) outputs of risk assessment conducted in order
to change therapy due to shortages (Supplementary Material).
The survey was initially piloted among five experienced hospital
pharmacists from separate countries involved in both clinical
practice and academia relating to issues of medicine shortages.
As all participants are experienced healthcare professionals who
can provide future direction, we have listed all participants as co-
authors in a similar manner to Bochenek et al. (2017).
As to enhance their robustness, the survey findings' accuracy
have been reviewed together with the co-authors. Study rigor was
additionally assured by including available published scientific
literature and legislation relevant to risk assessment as part of the
overall data analysis.
Both qualitative and quantitative data analyses were
performed following a case-oriented methodological
framework in order to encompass all aspects of risk mitigation
strategies applied (Yin, 2003). Тhe quantitative data analysis was
conducted with Microsoft Office Excel 2010 and IBM SPSS
Statistics® using descriptive statistics based on the distribution
of responses expressed in percentages. The percentage next to
each rating in the survey results represents the percentage of total
respondents that selected a respective answer. The difference in
proportions was tested by the chi-square test and Fisher's exact
test for independence, while differences in the observed ordinal
variables were tested by the Mann-Whitney or Kruskal-Wallis
test. The qualitative data were examined, categorized, tabulated
and recombined with quantitative data in order to observe, reveal
and interpret meanings and patterns, and construct conclusions.Frontiers in Pharmacology | www.frontiersin.org 4No ethical approval, neither written informed consent from
participants, were sought for this study as the information
obtained via the survey was practice-base oriented and publicly
available. In addition, the healthcare professionals freely
participated and no patients were involved, as in line with
similar such studies in this and related fields (Godman et al.,
2014; Moon et al., 2014; Bochenek et al., 2017). Due to the subject
matter not concerning patients nor private information, no
institutional ethical approval was required by the authors'
home countries nor called for by any specific guidelines.
Twenty-four countries that are members of the COST Action
15105 were included in this study, 20 from the European Union
(EU) and 4 non-EU.RESULTS
Overall, there were 34 responses from 24 countries (out of the
then 28 total COST Action 15105 countries), response rate:
85.7% (Table 1).
The majority of the participants work as hospital pharmacists
(67.6%—23 participants), while those representing the
community/wholesaler pharmacists were lowest in proportion
to the total number of all participants (5.8%—2 participants).
Risk Assessment as a Medicine Shortage
Mitigation Strategy
The findings here indicate that five European countries have
defined acts addressing shortages, which require risk-assessment
implementation should a medicine shortage occur. See Table 2
for risk assessments embedded in the legislation by respective
country including those where this is expected to happen in the
near future.
Generally for life saving medicines (i.e., antibiotics,
immunoglobulins oncology medicines and vaccines1—see
Table 3), national authorities perform risk assessment for
medicines affected by shortages in Denmark, Finland,
Germany, Hungary, and Italy. Irish and UK medicine shortage
management guidelines that encompass risk assessments have
been developed (Health Products Regulatory Authority (HPRA),
2018; Root, 2018). Switzerland initiated risk assessment 18 years
ago in practice (the Swiss Federal Act on Medicinal Products and
Medical Devices). Hungary has only recently implemented risk
assessment (Government of Hungary, 2006)
Although Acosta et al., 2019 reported numerous publications
addressing multiple aspects of shortages in Europe, including
their mitigation (Acosta et al., 2019), our findings show that 22
(64.7%) of all survey participants were unaware of any published
governmental or non-governmental documents on applied risk
assessment dedicated to shortages in their respective country.
Twenty-nine of 34 (85.3%) were also not informed on any
impact assessment of a respective shortage-mitigation strategy
(see Table 4).March 2020 | Volume 11 | Article 357
Miljković et al. Medicine Shortages in Europe and IsraelThe participants (61.7%) are aware of the use of risk
assessment procedures as a coping strategy for medicine
shortages (Table 4). Twenty-seven participants named the
particular risk assessment procedure they are familiar with:
26.4%—the FMEA, 23.5%—RCA, 14.7%—the HFMEA andFrontiers in Pharmacology | www.frontiersin.org 514.7%—the HACCP (Table 4). 52.9% described risk-
assessment steps. The participants from Bosnia and
Herzegovina, Denmark, Ireland, and Switzerland noted an
approach more oriented to a retrospective risk analysis.
Finnish and French participants report identifying root causes;TABLE 1 | Participant background (region, occupation, number of hospital pharmacists by pharmacy and population).
Number of
respondents
%*
Participants 34 100
EU-countries 25 73.5
Non-EU countries 9 26.5
Europe
Northern 5 14.7
Central 6 17.6
Western 4 11.7
South-eastern 19 55.8
Occupation and participants’ countries
Hospital pharmacist (Austria, Bosnia and Herzegovina, Belgium, Croatia, Cyprus, Greece, Estonia, France, Germany, Hungary, Ireland,
Latvia, Montenegro, Norway, Romania, Slovenia, Serbia, Switzerland)
23 67.6
Community pharmacist (Bosnia and Herzegovina; Montenegro) 2 5.8
Wholesaler pharmacist (Denmark) 2 5.8
Agency-regulatory pharmacist (Serbia, Finland, Bosnia and Herzegovina) 3 8.8
Medical doctor (Bosnia and Herzegovina, France) 3 8.8
Clinical system manager (Israel) 1 2.9
Number of hospital pharmacists per pharmacy in the participants’ country**
< 5 22 64.7
5–9 7 20.6
> 10 5 14.7
Number of hospital pharmacists per 100,000 population in the survey respondents’ country**
< 5 15 44.1
5–9 11 32.3
> 10 8 23.5March 2020 | Volume 11 | Article*Due to rounding, some totals may not correspond with the sum of the separate figures.
**Data was obtained via the country reports of spring 2018. The information is based on data included in the 2017 results for the EAHP Statement survey. (Horak et al., 2018)TABLE 2 | Participants’ answers according to risk assessment embedded in legislation on medicine shortages.
Country Access to information on
alternatives via national
shortages databases*
Legislation act Access
Belgium Existing information on
available alternatives, with
additional details
Royal decree 1885 will be updated with the bill 55K229 on
medicine shortages coping strategies including risk assessment by
31 January 2020
https://www.rtbf.be/info/belgique/detail_la-chambre-
approuve-une-proposition-de-loi-contre-la-penurie-
de-medicaments?id=10392783
Bosnia and
Herzegovina
No data base available Medicinal products and medical devices Act (“Official Gazette of
B-H, no.58/08”) (Government of Bosnia and Herzegovina, 2008)
http://www.almbih.gov.ba/en/_doc/regulative/
medicinal_products_and_medical_devices_act.pdf
Denmark Existing information on
available alternatives, with
additional details
The Danish Medicine Agency regulation on reporting obligation for
drug suppliers in Denmark (Danish Medicines Agency, 2018)
https://laegemiddelstyrelsen.dk/da/godkendelse/
kontrol-og-inspektion/alvorlige-
forsyningsvanskeligheder/#
France No information provided Décret n° 2016-993 du 20 juillet 2016 relatif à la lute contre les
ruptures d'approvisionnement de medicaments (Le Gouvernement
français, 2016)
https://www.legifrance.gouv.fr/affichTexte.do?
cidTexte=JORFTEXT000032922434&categorieLien=
id
Hungary Existing information on
available alternatives, without
additional details
Act XCV of 2005 on Medicinal Products for Human Use and on
the Amendment of Other Regulations Related to Medicinal
Products (Government of Hungary, 2005)
https://net.jogtar.hu/jogszabaly?docid=a0500095.
tv&dbnum=62&getdoc=1
Serbia No data base available Law on Medicines and Medical Devices (The Official Gazette of the
Republic of Serbia, 2010)
https://www.alims.gov.rs/eng/regulations/law-on-
medicines-and-medical-devices/
Switzerland No information provided The Swiss Federal Act on Medicinal Products and Medical Devices
(Therapeutic Products Act) and its ordinances (The Federal
Assembly of the Swiss Confederation, 2000)
https://www.admin.ch/opc/en/classified-
compilation/20002716/201901010000/812.21.pdf*According to EMA – European Medicines Agency or available literature for non-EU countries.
TPA, Therapeutic Products Act.357
Miljković et al. Medicine Shortages in Europe and Israelanalyzing risks and prioritizing needs, proposing alternatives
according to recommendations. The latter do so according to the
Agence Nationale de sécurité du Médicament et des produits de
santé (ANSM) and The Haute Autorité de santé (HAS). 44.1%
implement risk assessment in their daily work. Multidisciplinary
teams (35.3%) consisting of physicians, pharmacists, nurses, and
quality/procurement office members (20.6%; 17.6%; 11.7%; and
20.6%, respectively) conduct assessments (Table 4). Answers
from Austria, Bosnian and Herzegovina, Denmark, and Finland
reveal that such teams may have different members depending on
the assessment; such as reconstitution of medicines, cross-
departmental processes, quality control, logistics, and supply chain.The Structure and Process of Risk
Assessment Procedures via Triage
Risk triage in practice is not universal. Whereas 10/34
participants from seven countries (29.4%) stated they apply
risk assessment procedures in everyday work, 24 participants
(70.6%) from 13 countries do not consider risk assessment to be
currently integrated into their work to establish such strategies.2
Doing so requires a significant amount of time. This is born out
in the findings where actively working on shortage mitigation
accounts for slightly more than 10% of full-time equivalents
(FTE) in Belgium, while it is approximately 5% in Finland and
30% in Norway. For those having risk assessment procedures in
place, their update is conducted quarterly in France, Hungary,
Switzerland, and the UK, monthly in Norway, annually in Bosnia
and Herzegovina, and every 2 to 3 years in Finland.
The participants do recognize a variety of risks where medicine
substitution is an important risk in eleven countries (Table 5).
These risks also include insufficient single-dose barcode packs,
available medicine in non-uniform concentrations, look-alike/2The time invested in managing shortages, including risk assessment, is found to
span from up to one or two hours per day in Romania and Greece to ten hours per
week in Ireland.
Frontiers in Pharmacology | www.frontiersin.org 6sound-alike (LASA) medicines, unknown preparation, and
administration methods as well as therapy duplication.
Moreover, MAHs are legally required to report a potential
shortage and its related risks to the health authorities (European
Medicines Agency (EMA) 2019b). In contrast, Bochenek states
that healthcare professionals implement reporting shortages
heterogeneously, which may even be done via voluntary,
informal networks but is not carried out by regulation
(Bochenek et al., 2017). This informal nature is also
conspicuous in our findings where there is an absence of
reporting risk-assessment results to government authorities,
with 30/34 participants (88.2%) not reporting their findings to
their respective official institutions while four participants from
Finland, Montenegro, Norway, and Romania, (11.8%) do so
(Table 4).The Implications of Risk Assessment
Procedures Regarding the Medicine
Shortage Mitigation Process
Seven of 34 (20.6%) participants apply risk assessment in
conjunction with increased stocks of medicines (held by the
manufacturer, wholesaler, or pharmacy) to respond to shortages.
Finland's Act on Mandatory Reserve Supplies requires that
predetermined groups of medicines based on risk assessment
are reviewed on a 2-year basis and that safety stocks are in place
(The Finish Medicines Agency (FIMEA), 2008).
Twenty-nine of 34 (85.3%) participants consider risk
assessment to be a useful mitigation strategy and 15/34
(44.1%) report to mitigate shortages successfully via risk
assessment (see Table 4). As presented in Table 6, participants
of eight countries consider strategies to be successful only if
patient harm is prevented in shortages. They also view strategies
as successful if: 1) they are able to compound medicine affected
by a shortage; and 2) they are able to prioritize patients based on
their clinical status to receive treatment (Table 6).
When shortages abruptly occur, only 3/34 (8.8%) participants
stated that they do keep records on how quickly they manage risk
assessment (Table 4). In Norway, it takes up to 24 h to assess risk
and provide guidelines on antibiotic substitution in cooperation
with their National Medicine Agency. Moreover, Norway's
National Centre for Medicine Shortages in Hospitals
reportedly performed more than 100 risk assessments in the
year preceding the survey. In addition, hospital pharmacists
routinely conduct formal practice-based assessments in every
day practice in Austria, Germany, and Hungary, even though
there are no formal risk assessment procedures for shortages
in place.
There are three factors among participants determining the
number of assessments conducted and procedures used in the year
preceding the survey: 1) a higher number of multidisciplinary
members on the team; 2) the participant being aware of risk
assessment; and 3) the participant implementing it in everyday
practice (p < 0.005) (Table 7). No geographical difference was
observed concerning the application of risk assessment, including
the density of hospital pharmacists in the participants' countries (p >
0.005) (Table 7).TABLE 3 | Medicines under risk assessment during shortages.
Medicine Country of survey participant (%)* of
total
Antibiotics France, Finland, Bosnia and Herzegovina,
Belgium, UK, Ireland, Austria
20.6
Oncology medicines Austria, Greece, Romania, Montenegro 11.8
IVIG Austria, Belgium, Finland, France, Romania 14.7
Blood products
(human albumin)
Austria, Belgium, Cyprus, Finland 11.8
Vaccines Austria, Belgium, Finland, France 11.8
Insulins Bosnia and Herzegovina, Finland 5.9
Oral anticoagulants Serbia 2.9
Diuretics (furosemid) Serbia 2.9
Nutritional liquids Finland 2.9
Adrenalin injections Finland 2.9
Antihypertensives Finland 2.9
Anesthetics Israel 2.9*Percentage of those who use risk assessment sorted by highest.
IVIG, immunoglubulins.March 2020 | Volume 11 | Article 357
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Selected survey questions and answers Number of responses %
Are you aware of any risk assessment procedures that can be used to mitigate medicine shortages? (answered “YES”) 21 61.7
The type of risk assessment:
FMEA 9 26.4
HFMEA 5 14.7
HACCP 5 14.7
RCA 8 23.5
Other 2 5.8
Where does risk assessment take place
Hospital pharmacy 9 26.5
Community pharmacy 2 5.8
Wholesaler facility 3 8.8
Healthcare authority 2 5.8
Are you able to describe the steps of the risk assessment procedures you are familiar with? (answered “YES”) 18 52.9
Do you implement risk assessment in your daily work? (answered “YES”) 15 44.1
Are you conducting risk assessment within multidisciplinary teams? (answer “YES”) 12 35.3
The type of professions included in the multidisciplinary team:
Physician 7 20.6
Pharmacist 6 17.6
Nurse 4 11.7
Quality control/procurement department 7 20.6
Answered “YES”,
Number of responses
%
Is there a defined act stipulating the implementation of risk assessment during medicine shortages embedded within legislation in your
country?
5 14.7
Are you aware of any other legislation which is to be implemented in the near future in your country? 4 11.7
Are you able to say how long risk assessment related to medicine shortages has been implemented in your country? 8 23.5
Are you aware of any initiative for the implementation of risk assessment related to medicine shortages expected to take place in the
near future in your country?
7 20.6
Are there any published, governmental or non-governmental documents on applied risk assessment in your country? 12 35.3
Are there any published governmental or non-governmental documents dedicated to studying ways to reduce the impact of medicine
shortages? Specifically, any documents related to applied risk assessment measures as a mitigation strategy in your country?
5 14.7
Are risk assessment procedures part of the medicine shortage protocols/mitigation strategy in your workplace? 10 29.4
When conducted, are you obligated to report on the results of the risk assessment to official institutions inside your country? 4 11.8
When completed, do you share the outcomes of the performed risk assessment for a specific medicine with other stakeholders in your
country (such as manufacturers, health authorities, national/private health-insurance funds)?
6 17.6
Do you perform risk assessment together with other medicine shortage mitigation strategies? 7 20.6
According to your professional experience, have you been able to mitigate medicine shortages successfully with risk assessment
procedures?
15 44.1
Do you keep records on how quickly you can manage risk assessment when a medicine shortage abruptly occurs? 3 8.8
Do you find risk assessment useful as a medicine shortage mitigation strategy? 29 85.3Frontiers in Pharmacology | www.frontiersin.org March 27 020 | Volume 11 | ArticleDue to rounding, some totals may not correspond with the sum of the separate figures.
FMEA, Failure Mode and Effect Analysis; HFMEA, Healthcare Failure Mode and Effect Analysis; HACCP, Hazard Analysis and Critical Control Points; RCA, root cause analysis.TABLE 5 | Risks detected while conducting risk assessment in medicine shortages.
Country Risks
Belgium, Bosnia and Herzegovina, France, Germany, Italy, Montenegro, Norway,
Romania, Serbia, Spain, the UK
Risk due to medicine substitution/different usage of alternative medicine/difference in
alternative's administration patterns
Bosnia and Herzegovina Risk from medication errors due to substitution
Bosnia and Herzegovina Risk from unforeseen adverse events due to substitution
Ireland Risk from miss-communication among stakeholders due to shortages
Belgium Risk from not having single barcodes packs due to shortages
Belgium Risk from look-alike/sound-alike medicines in substitution due to shortages
Ireland, Finland, Norway, Spain, Romania Risk for continuous medicine supply interruption in shortages
Switzerland Risk from depending on raw material providers situated in Asian countries in
shortages
France Risk of having to prioritize patients when it comes to dispensing medicines due to
shortages357
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All causes driving medicine shortages bare significant risks to
patient treatment (Birgli, 2013; Fox and McLaughlin, 2018).
Manufacturing problems are difficult to predict and account
for, both locally and globally, particularly when a single
manufacturer produces medicines for several MAHs (Health
Products Regulatory Authority (HPRA), 2018). For instance,
there has been a recent case indicating the potential human
carcinogenic impurity of N-nitrosodimethylamine (NDMA)
found in valsartan and ranitidine (Food and Drug
Administration (FDA), 2019; Food and Drug Administration
(FDA), 2020). This finding provoked unexpected shortages and
showed how healthcare professionals should be better informed
in order to mitigate them (Government of the United Kingdom,
2018; Government of the United Kingdom Department of
Health and Social Care, 2019b). Expected discontinuation in
production, limited capacity, and pharmaceutical industry
consolidation, however, are more predictable and, therefore,
manageable (Birgli, 2013).
Regardless of predictability, it is still necessary to be prepared for
shortages and to assess a variety of risks stemming from them.
Interruptions in medicine production and their supply chains may
occur due to a number of factors (quality, legal, economic, or
market). Moreover, there are substantial clinical and safety risks
when patients do not receive treatment or appropriate substitutes
(Parenteral Drug Association (PDA), 2014). These risks need to be
addressed in a proactive manner in order to reduce harm, assure
patient safety and optimize health outcomes. To the best of our
knowledge, we believe this is the first paper to address theFrontiers in Pharmacology | www.frontiersin.org 8application of prospective risk assessment in medicine shortages
in healthcare across Europe.
Currently, the latest guidelines on managing shortages
proposed by the ASHP, the TGA, and the EMA are based on
risk assessment involving both manufacturing and distribution
processes, as well as possible risks to patients when introducing
therapeutic alternatives (Australian Government Department of
Health, 2018; Fox and McLaughlin, 2018; European Medicines
Agency (EMA) 2019a; European Medicines Agency (EMA)
2019b; European Medicines Agency (EMA) 2019a). The Israeli
Ministry of Health conducts a protocol for healthcare
professionals, managers, and importers to carry out risk
assessment to propose solutions implemented nationally if no
generic alternatives are available (Schwartzberg et al., 2017).
According to the NHS' Department of Health and Social Care,
performing risk assessment for joint procurement is
recommended to avoid local duplication (Root, 2018;
Government of the United Kingdom Department of Health
and Social Care, 2019a). The National Patient Safety Agency's
(NPSA) rapid response report emphasizes the risk posed by a
lack of medicine and its potential impact on patients. Here, risk
factors particularly relate to a determined medicine-group that
may be pre-defined according to treatment delay, facilitating the
work of healthcare professionals, and equipping them with the
necessary tools needed to prevent harm from delayed or omitted
treatment (UK Medicines Information, 2010).
There is a growing awareness of risk-management strategies
that prospectively assess risks from shortages by focusing on
national-legislation and regulatory-framework mapping that
involves “out-of-stock” situations (Acosta et al., 2019).
However, addressing these risks does not require any
assessment that may occur following or prior to substitution.
To illustrate, a survey on clinical risk management (Manser et al.,
2016) revealed a significant variability in the implementation of
risk assessment methods where 43% and 31% of hospitals report
no use of the FMEA or RCA in clinical risk management.
Given this variability, it follows that only 18 out of 34
participants of our survey reported being aware of the steps
necessary to carry out a risk assessment. While 61.7% of
participants in this study are aware of risk assessment
applicable in medicine shortages, 44.1% apply it in everyday
practice. According to the survey, participants from seven
countries are aware of RCA to be used to mitigate shortages,
while 14 participants from nine countries acknowledged FMEA/
HFMEA as a risk assessment tool in shortages. It is then
questionable if RCA is a tool to be implemented in risk
assessment stemming from medicine shortages. Bonnabry et al.
views RCA as a suitable methodology when incidence/errors are
frequent; however, retrospective methods are not deemed
suitable for low incidence or difficult to predict situations
(Bonnabry et al., 2005). Assessing risks after a failure is
entirely unacceptable since the patient's health outcomes may
be detrimental (Bonnabry et al., 2005). Consequently, having a
more prospective approach to manage high risks in healthcare
processes, similar to the aviation industry, has received greaterMarch 2020 | Volume 11 | Article 357TABLE 6 | What is considered to be a mitigation success in shortages among
participants.
“What is a success in mitigating shortages?” Country
“When we don't have to let patients untreated.” Germany
“No obvious harm to patients.”; “The shortage was managed
without patient harm.”; “Preventing harm to patients through
overcoming complete medicine shortages and finding
alternatives.”
Bosnia and
Herzegovina,
Ireland,
Serbia, UK
“Shortages were not met by healthcare professionals and
patients.”
Finland
“The number of reported shortages in Norway is growing rapidly
but the extra cost is reduced. The time spent at each hospital
handling shortage is not growing proportionally to the increase in
reported shortages.”
Norway
“We managed to get necessary medicines.” Slovenia
“Keeping the medicine for vulnerable population-those who
cannot be treated with alternative.”
Israel
Switzerland
“Efficient prioritization of patients and effective communication
with a physician”
France
“Rational use of product severely affected by a shortage or
providing a suitable alternative”
Belgium
“Being able to redistribute a medicine, compound or import it.”;
“Having tools for: 1. Communicating if a product is in shortage to
the prescribers and nurses 2. Drug shortage catalogue and
reporting systems (institutional and national) 3. Finding alternative
sources (e.g.: importation) 4. Change in formulary”
Hungary
Miljković et al. Medicine Shortages in Europe and Israelacknowledgement and has become more accepted among
healthcare professionals since 2002 when the FMEA was
transformed into the HFMEA (DeRosier et al., 2002; Bonnabry
et al., 2005; Kurgat et al., 2019). The sterilization of surgical
instruments and the intravenous administration of medicines
already implemented these approaches (Wetterneck et al., 2004;
Linkin et al., 2005; Kurgat et al., 2019). By proactively detecting
shortage risks, health professionals may establish therapeutic
alternatives in advance especially for critical medicines in order
to allow healthcare providers to be ready if shortages occur. TheFrontiers in Pharmacology | www.frontiersin.org 9survey results reflect these findings, where more participants
(35.2%) opted for prospective compared to retrospective (26.4%)
risk assessment.
Although slightly more than half of all participants were aware of
risk assessment as a tool to mitigate medicine shortages, only 4 out
of 17 applied it to hospital pharmacies. Bearing in mind that the
majority of participants are hospital pharmacists, this result does
reflect their particular outlook as healthcare professionals.
Only participants from five countries 5/34 (14.7%) stated that
their respective legislation stipulating the implementation of riskTABLE 7 | Differences in observed ordinal variables.
Participants by geographical
region; density of hospital
pharmacists; survey questions
regarding the implementation
of risk assessment
The number of risk assessments performed in the year
preceding the survey
The number of different risk assessment procedures used by
the participants
Mean rank Median [IQR] p-value* Mean rank Median [IQR] p-value*
European region
Northern 16.67 50 [25–75] 0.374 14.25 1 [0.5–1.5] 0.634
Central 8.38 0[0–2] 15.25 0.5 [0–1]
Western 13.67 5 [2.5–5.5] 18.88 1 [0.5–1]
Southeastern 11.65 1 [0–4] 19.03 1 [0–2]
Number of hospital pharmacists
per 100 000 of the population
<5 10.60 0 [0–4] 0.478 19.43 1 [0–2] 0.356
5–9 10.71 1 [0–2.5] 15.48 1 [0–1]
>10 14.40 5 [0–50] 14.71 1 [0–1]
Number of hospital pharmacists
per pharmacy
< 5 10.10 1 [0–13.5] 0.281 16.02 1 [0–1.5] 0.661
5–9 14.88 4.5 [2–27.5] 19.50 1 [0.5–1]
>10 14 3 [1.5–51.5] 17.60 1 [1–1.5]
Number of professionals in the risk
assessment team
0 8.36 0 [0–1] 0.012 16.26 0 [0.5–1] 0.340
1 15.33 6 [3–33] 17.38 1 [0.5–1.5]
3 21 55 [10–100] 22.50 1 [1–1]
4 16.67 5 [0.5–8.5] 24.63 1 [1–1.5]
Are you aware of any risk
assessment procedures
that can be used to mitigate
medicine shortages?
No 9.64 0 [0–2] 0.278 8 0 [0–0] < 0.001
yes 13.03 2.5 [0–8] 23.38 1 [1–2]
Do you implement risk
assessment in your daily work?
No 7.96 0 [0–0.5] 0.002 14.95 0 [0–1.5] 0.048
Yes 16.41 6 [3–31] 20.73 1 [1–1]
Are risk assessment procedures
part of the medicine shortage
protocols/mitigation
strategy in you workplace?
No 8.63 0 [0–0.5] < 0.001 15.28 0 [0–1.5] 0.123
Yes 18.31 8 [4.5–31] 20.95 1 [1–1]
Do you perform risk assessment
together with other medicine
shortage-mitigation strategies?
No 10.17 0 [0–4] 0.012 16.54 1 [0–1] 0.620
Yes 18.60 12 [5–50] 18.71 1 [1–1]March 2020 | Volum*p-value estimated by Mann-Whitney or Kruskal-Wallis test, when appropriate.
Mean rank assigned to ordinal variables corresponding to the participants' characteristics and their answer.
IQR, interquartile range.e 11 | Article 357
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According to most participants (26/34—76.4%), there are no
changes to legislation in their respective countries in the near
future. Their responses point to a lack of the integration of risk
assessment into mitigating shortages. Therefore, the creation of
legislative tools facilitating healthcare professionals in
establishing and meeting risk-assessment objectives is
recommendable via a proactive, prospective and preventative
manner, rather than a reactive and retrospective one
(Clarkson, 2010).
In line with recommendations for managing shortages (Ordre
des pharmaciens du quebec service des communications, 2012;
Health Products Regulatory Authority (HPRA), 2018), 12/34
par t i c ipan t s (35 .3%) per form r i sk as se s sment in
multidisciplinary teams, thereby promoting the equitable use
of scarce resources and prioritizing treatments (Chiozza and
Ponzetti, 2009; Health Products Regulatory Authority (HPRA),
2018). A majority of participants noted that nurses and
pharmacist technicians are included as multidisciplinary team
members. In Belgium, members may be chief medical or
executive officers, as well as in Finland. Having executives on
team provides support to the implementation of treatment plans
and shortage-mitigation guiding procedures. A list of medicines
detailing what consequences may occur if the medicine becomes
unavailable is also crucial. The participants cite a list following a
similar global pattern of frequent shortages described in Acosta
et al. (2019).
Fifteen of 34 (44.1%) participants reported implementing risk
assessment in their daily work, while 24/34 (70.6%) do not have risk
assessment integrated within medicine-shortage mitigation protocols.
As reported, the lack of integrated risk assessment confirms that risk
assessment is implemented empirically, based on experience,
knowledge and the competences of the healthcare professionals,
rather than from following structured, defined procedures.
Already having risk assessment guidelines in place allows for
healthcare professionals to take individual patient profiles into
account, including a patient's clinical status and comorbidities.
According to the ASHP, every healthcare setting should perform
an impact analysis in order to assess the effect of a shortage on
work processes in a hospital pharmacy and its consequences for
clinical outcomes (Fox and McLaughlin, 2018). Patients must be
under supervision so that alternative medicines may be
introduced where appropriate. Risks from increased adverse
effects and deteriorated health must be taken into account
before deciding on a substitute medicine (Fox and McLaughlin,
2018; Root, 2018).
The participants' high response rate does reflect the
continuing problems in medicine shortages where they pointed
to potential health risks associated with substitution (particularly
with a medicine's reconstitution, administration patterns, dosing,
stability, and adverse events profiles). The participants also
widely acknowledge incorporating risk assessment and how
critical medicine is to developing medicine guidelines to reduce
potential harm from an interrupted or delayed treatment. This is
in concordance with the Royal Dutch Society of Pharmacists who
provide pharmacist-gathered data and supply-chain updates onFrontiers in Pharmacology | www.frontiersin.org 10the Farmanco website to inform on a shortage's probable cause,
its duration, and potential alternatives (The Royal Dutch
Pharmacists Associat ion (KNMP), 2019) . Through
disseminating and sharing information on the substitution of
medicines, healthcare professionals are supported in shortages
(The Royal Dutch Pharmacists Association (KNMP), 2019).
Although Australia, Canada, and the US update their databases
regularly, (Vida et al., 2016; Acosta et al., 2019), the majority of
shortage-reporting systems in Europe do not do so frequently as
well as do not appear to have information on possible substitutes
and clinical guidance for healthcare professionals (European
Medicines Agency (EMA), 2019a).
There is no report of the 2013 EMA guiding document
describing resources for issuing treatment recommendations
during shortages. Although this guiding document does not
provide the means to use such recommendations on a patient-
impact analysis for risk assessment, it does establish the foundation
of a further document (issued 3 years later) describing criteria to
establish and distinguish critical from non-critical medicine
shortages based on patient-health consequences (European
Medicines Agency (EMA), 2013). It is of concern that only one
participant refers to these documents since it may suggest that
healthcare professionals are not actively using or consulting them.
The participants also made no reference to subsequent templates for
risk indicators for shortages issued by the EMA in 2015 that focus
on manufacturing and quality issues (European Medicines Agency
(EMA), 2015). The EMA also issued two more documents in 2019
(outside the survey time) that notify on shortages and
communication to the public (European Medicines Agency
(EMA), 2019a; European Medicines Agency (EMA) 2019b). The
communication document provides a list of databases on
alternatives with accompanying details on their application in
Denmark, Germany, and Norway, among others (European
Medicines Agency (EMA), 2019a). Based on our findings, we are
led to believe that the EMA should domore with its communication
strategy since the participants reference none of these documents.
Working in cooperation with healthcare professionals' associations
across Europe could better serve to disseminate information and
facilitate management of medicine shortages at all healthcare
settings, as they would be the best channels to promote and
inform on the aforementioned documents.
The survey results demonstrate wide variation concerning the
time needed to manage a shortage via risk assessment, stretching
from 1 to 20 h per week. The literature confirms this variation in
Europe (Caulder et al., 2015; Pauwels et al., 2015; Miljkovic et al.,
2019). Developing tailor-made measures to mitigate shortages
does remain a challenge due to time concerns among
some participants.
Sharing information is a cornerstone of the new strategy for
combating shortages issued by the FrenchMinistry of Health, which
emphasizes that both patients and healthcare professionals have the
right to transparent and timely information on medicine shortages
(France Assos Santé, 2018). It is therefore of concern that risk-
assessment based outputs are typically not shared with other key
stakeholders participating in mitigation, as stated by 27/34
(79.4%) participants.March 2020 | Volume 11 | Article 357
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improve shortage management via risk assessment, 23/34
(67.6%) participants make no mention of their application in
Europe. Furthermore, since 30 (88.2%) participants reported not
being aware of any published document/publication that
describes how to reduce the impact of medicine shortages,
initiatives intended for handling medicine shortages need
better dissemination and application. These should not only be
based on creating and enforcing databases for collecting
information on medicines affected by shortages, but also apply
approaches based on risk management tailorable to country
specifics and prospectively address shortages (Acosta
et al., 2019).
Numerous guidelines state that shortages are best handled
prospectively (Institute for Safe Medication Practices Canada,
2006; Parenteral Drug Association (PDA), 2014; Fox and
McLaughlin, 2018). Accordingly, 15 (44.1%) participants
reported successfully mitigating medicine shortages through
risk assessment, while 29/34 (85.3%) considered risk
assessment useful for mitigating shortages. Ultimately, the
majority of participants share the view that not exposing
patients to harm stemming from medicine shortages is the
main outcome of successfully-led mitigation. In order to assess
if there may be any harm to patients originating from shortages,
it is important to tailor tools that could assist in recording and
sharing the impact of shortages as well to create treatment
guidelines addressing shortages (Phuong et al., 2019). This
includes potential replacement treatments when the need arises.
Limitations of the Study
Although this study aimed at capturing a European perspective
regarding risk assessment in medicines shortages, there are a
number of limitations. It can be difficult to draw vigorous
conclusions from research based on conducted surveys due to
issues regarding the recruiting of participants and having a
representative sample (Banerjee et al., 2014). Participants
might also provide answers expected to be more acceptable,
which may affect the validity of the research findings (Beiderbeck
et al., 2004). The majority of answers also came from hospital
pharmacists, which severely limits conclusions compared to
wider healthcare and multi-stakeholder scales. Study
participants also provided answers based on their own
knowledge and experience. While these are supported by the
literature and available guidelines for risk assessment, it still
cannot eliminate all possible biases. Moreover, only COST
Action 15105 members, hospital pharmacist EAHP members
and their associated colleagues were involved in this study, while
other healthcare professionals/stakeholders that might be
involved in medicine shortage mitigation across Europe did
not participate and provide their feedback in this study.
Finally, although it would be of assistance to relate the type of
risk detected with the specific medicines affected by a shortage
among the participants, it was not included in the original survey
as the purpose was to focus directly on risks detected emerging
from risk assessment (see Table 5). Therefore, single medicines/
substances are not able to be listed directly within this study byFrontiers in Pharmacology | www.frontiersin.org 11their International Nonproprietary Names. This limitation
should be remedied in further studies.CONCLUSION AND RECOMMENDATIONS
Our study points to a lack of systematically organized tools used
to prospectively analyze clinical as well as operationalize risk
stemming from medicine shortages in healthcare. Although, the
awareness of prospective risk assessment does exist among
healthcare professionals, there currently appear to be a lack of
legal instruments and sufficient data confirming the necessity
and usefulness of risk assessment in mitigating medicine
shortages in Europe. As a result, it is recommendable that
healthcare professionals be given the skills to perform risk
assessment via established protocols integrated into their
everyday work.
Risks originating from medicine substitution when shortages
occur are the main reported concern of the majority of the
participants. Through the prospective identification and
description of potential risks, healthcare professionals may
better account for and manage the likelihood and severity of a
shortage's impact. Notwithstanding, the risk assessment outputs
provided have typically been seen or not shared among all key
stakeholders. In view of the discrepancy, it is suggested that
multi-stakeholder communication is necessary in order to avoid
duplication of efforts and to assure effectiveness of medicine-
shortage mitigation measures. This should be a subject of
future research.
The participants perform risk assessment equally for
particular medicines, such as immunoglobulins, blood
products, and those for oncology as well as for essential
medicines such as antibiotics, oral anticoagulants, diuretics,
and antihypertensives. Assessment therefore knows no
difference when risks to patient health needs are evaluated and
potential harm is prevented. However, without an integrated
structure in the workplace, risk assessment does not achieve its
full potential.
All key stakeholders involved in managing medicine shortages
should consider combining their efforts through conducting
proactive and prospective risk assessment in a harmonized
manner to support patient harm reduction. It is particularly
important in hospitals where there are manpower issues. Hospital
pharmacies employing more staff do perform more risk assessment
compared with pharmacies with fewer staff. For this reason, apart
from lack of skills in conducting risk assessment, there is insufficient
available staff who are able to carry out risk assessment, despite its
positive impact on patient safety. This insufficiency of staff must be
addressed going forward. Moreover, greater information technology
support is needed in carrying out risk prevention strategies via
developing and providing a list of agreed substitutable medicines
during shortages across countries. Key stakeholders within hospitals
may undertake list development as part of Drug and Therapeutic
Committee activities aimed at better handling medicine shortages.
A prospective approach in risk assessment not only allows the
risks to be handled systematically in a timely manner, but alsoMarch 2020 | Volume 11 | Article 357
Miljković et al. Medicine Shortages in Europe and Israelprovides and influences a safety culture within healthcare
settings. Through empowering healthcare professionals as
active participants and not a mere spectator of ongoing risks
stemming from shortages, it is possible to provide a safer
environment for patients across healthcare settings.
Consequently, based on participant responses, healthcare
professionals must also invest greater effort to reduce adverse
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